Heart Failure

SPIRIT-HF reported neutral outcomes for spironolactone in HFpEF/HFmrEF, but ongoing analyses may clarify which patients benefit most.

Finerenone lowered cardiovascular death and HF events irrespective of coronary heart disease status but did not reduce atherothrombotic outcomes.

Medically tailored meals and produce show feasibility but no reduction in 90-day readmissions, according to one study.

Strength and aerobic training improves cardiorespiratory fitness, functional capacity, and muscle strength more than aerobic exercise alone in heart failure.

Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch block, despite lower costs.

Left bundle-branch pacing significantly lowered the combined risk of death or heart failure hospitalization compared with conventional biventricular pacing.

A new study finds one-third of ambulatory patients with heart failure with reduced ejection fraction overestimate their life expectancy.

High area level housing cost burden is associated with increased cardiovascular hospitalizations and emergency department use among Medicaid beneficiaries.

Incorporating triglyceride-glucose-body mass index can help better account for metabolic impacts in patients with hypertension and heart failure with mildly reduced ejection fraction.

Patients with heart failure tended to have lower treatment intensity at hospital admission, but their cardiac load improved as blood pressure treatment intensified.

An analysis shows that oral semaglutide significantly lowers the risk of heart failure (HF) outcomes in patients with type 2 diabetes and a history of HF.

Lower income and higher social deprivation were associated with increased heart failure and arrhythmia risk in patients with hypertrophic cardiomyopathy.

A meta-analysis found β-blockers did not improve clinical outcomes in patients with acute MI and preserved LVEF, raising questions about routine use.

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Heart failure deaths increasingly occur at home or in hospice, but racial, sex, and regional disparities persist in end-of-life care.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

Guideline-recommended HF therapies do not improve major outcomes in Chagas disease, though sacubitril/valsartan improved NT-proBNP levels, new data show.

Non-DNMT3A CHIP subtypes raised heart failure risk in a recent analysis, offering new insights for prevention and targeted management.

Scientists restored the CCNA2 gene in adult human heart cells, enabling them to divide and form new functional cardiomyocytes—advancing heart repair therapies.

Guideline-directed medical therapy used with remote monitoring can potentially reduce hospitalization in patients with heart failure with ejection fraction.

Aggressive lifestyle and risk factor control after ablation significantly lowers atrial fibrillation recurrence and improves heart health.

Increases in global temperatures may exacerbate cardiovascular mortality risk in older patients with heart failure.

Heart rate variability (HRV) biofeedback may be a potential intervention for patients with coronary artery disease.

Papillary muscle scarring (papSCAR) was found to be associated with increased risk of cardiac death in patients with dilated cardiomyopathy

Panelists discuss how effective heart failure management requires collaborative care across multiple specialties (primary care, cardiology, endocrinology, nephrology) with advanced practice providers serving as dedicated coordinators, utilizing multidisciplinary teams and algorithm-driven care protocols to optimize patient outcomes and prevent the hot potato approach to complex comorbidities.